Smartphones and Intelligent Socks to Help Prevent Diabetic Amputations

Diabetic neuropathy is a type of nerve damage associated with the development of foot ulcers in patients with diabetes. Resulting from anatomical deformation, excessive pressure and poor blood supply, it affects over 130 million individuals worldwide. It is also the leading cause of amputation, costing the United States economy alone more than $10 billion annually.

Diabetic patients are encouraged to get regular checkups to monitor for the increased pressure and ulceration that can eventually require amputation. However, ulcers are only diagnosed after they occur, meaning that patients require healing time, which dramatically increases healthcare costs.

Members of the BioDesign: Medical Innovation program, created by The Hebrew University of Jerusalem and its affiliated Hadassah Medical Center, set out to solve this problem.

"This is a significant medical problem that affects the lives of millions. We thought there must be a way to avoid these wounds altogether," said Danny Bavli, the group's lead engineer.

To address this challenge, Bavli partnered with Sagi Frishman and Dr. David Morgenstern, a leading orthopedic surgeon at Hadassah Medical Center. Together with other members of the Hebrew University BioDesign group, they developed SenseGO, a machine-washable sock containing dozens of micro-fabricated pressure sensors.

With SenseGO, changes in pressure due to incorrect posture, anatomical deformation or ill-fitting shoes are registered as electrical signals that are relayed to a smartphone app, which in turn informs the patient of developing risk.

Prof. Yaakov Nahmias, BioDesign program director, said: "This is a classic mobile health approach. By giving patients and their families the tools they need to prevent the development of ulcers, we can dramatically reduce health care costs related to diabetes."

Other members of the BioDesign SenseGO team included Inbal Boxerman and Yael Hadar, MBA students at The Hebrew University of Jerusalem.

BioDesign: Medical Innovation is a multi-disciplinary, team-based approach to medical innovation, created by the Hebrew University of Jerusalem and its affiliated Hadassah Medical Center. Sponsored by Boston Scientific and the Terumo Medical Corporation, the program takes outstanding medical fellows, bioengineering and business graduate students, and tutors them in the science and practice of bringing a medical innovation to the market. The program is directed by Prof. Yaakov Nahmias, director of the Alexander Grass Center for Bioengineering at the Hebrew University of Jerusalem, and Prof. Chaim Lotan, director of the Heart Institute at Hadassah Medical Center.

The innovations produced by the Biodesign program participants are commercialized by Yissum, the technology transfer company of the Hebrew University of Jerusalem, and Hadasit, the technology transfer company of the Hadassah Medical Center.

Most Popular Now

Mental Health Mobile Apps Are Effective …

When it comes to strengthening your mental or emotional health, would you trust an app? A trio of Brigham Young University health science researchers has published new research that says...

Virtual Reality for Bacteria

Scientists at the Institute of Science and Technology Austria (IST Austria) have managed to control the behavior of individual bacteria by connecting them to a computer. The interdisciplinary team including...

Social Mobile Gaming Boosts Rehabilitati…

The researchers from Imperial have designed a video game called Balloon Buddies, which is a tool that enables those recovering from conditions such as a stroke to engage and play...

Open Call SC1-HCC-03-2018: Support to Fu…

Citizens in ageing populations wish to stay in their homes for as long as possible. They are however at risk of age related impairments such as poor health, cognitive impairment...

New Software can Verify Someone's Identi…

In the science-fiction movie Gattaca, visitors only clear security if a blood test and readout of their genetic profile matches the sample on file. Now, cheap DNA sequencers and custom...

Philips to Help Develop AI and Machine L…

Royal Philips (NYSE: PHG, AEX: PHIA), a leader in health technology, is pleased to be associated with the government's recently announced £4.7 billion Industrial Strategy Challenge Fund. Working with public...

Open Call SC1-HCC-05-2018: Support to a …

The Communication on the mid-term review of the implementation of the Digital Single Market Strategy (COM(2017)228) identified three priorities on digital transformation of health and care (DTHC): citizens' access to...

Roche to Acquire Viewics, Inc. to Provid…

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced an agreement with Viewics, Inc., a privately held software company focused on laboratory business analytics. Under the agreement, Roche is acquiring all...

Philips Expands its Radiology Solutions …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has acquired US-based start-up company Analytical Informatics, Inc., complementing its own innovation initiatives to...

Philips Expands its Population Health Ma…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has acquired VitalHealth, a leading provider of cloud-based population health management solutions for the...

West of Scotland Creates Regional Portal

Scottish health boards covering a population of 2.2 million people are able to share patient information now that a two-year project to create a regional portal has been completed. Five...